Dr. Brian B. Johnson, MD
Mohs Surgery (MOHS-Micrographic Surgery Physician)
5630 Lowery Rd Ste 200
Norfolk, VA 23502
Who else practices at this address →
Norfolk city is a federal dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Eastern Virginia Medical School (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 587
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Eastern Virginia Medical School
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
VA license 0101279110 -
Dermatology Physician
NY license 295178 · PA license MD478832 · VA license 0101279110
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Anne Arundel Dermatology PA (127 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 587
- Services billed
- 2,597
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,004 | 163 |
| Established patient office or other outpatient visit, 20-29 minutes | 321 | 238 |
| Destruction of precancer skin growth, 1 growth | 250 | 195 |
| Established patient office or other outpatient visit, 30-39 minutes | 173 | 125 |
| Biopsy of related skin growth, first growth | 116 | 103 |
| Destruction of skin growth, 1-14 growths | 92 | 84 |
| New patient office or other outpatient visit, 30-44 minutes | 50 | 50 |
| Destruction of precancer skin growth, 15 or more growths | 37 | 31 |
| New patient office or other outpatient visit, 45-59 minutes | 34 | 34 |
| Biopsy of related skin growth, each additional growth | 29 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 61 payments worth $14,518 in total to this clinician.
| Janssen Biotech, Inc. | $12,753 |
|---|---|
| Galderma Laboratories, L.P. | $346 |
| Amgen Inc. | $326 |
| AbbVie Inc. | $299 |
| Novartis Pharmaceuticals Corporation | $274 |
| Genzyme Corporation | $179 |
| Regeneron Healthcare Solutions, Inc. | $148 |
| UCB, Inc. | $61.24 |
| Consulting Fee | $6,300 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,188 |
| Food and Beverage | $1,908 |
| Education | $71.76 |
| Travel and Lodging | $50.40 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jun 28, 2025 | Consulting Fee TREMFYA · Immunology | $6,300 |
| Janssen Biotech, Inc. Nov 1, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,475 |
| Janssen Biotech, Inc. Nov 8, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $2,475 |
| Janssen Biotech, Inc. Oct 11, 2025 | Compensation for services other than consulting (speaking, faculty) TREMFYA · Immunology | $1,238 |
| Janssen Biotech, Inc. Jun 9, 2025 | Education TREMFYA · Immunology · in-kind | $64.99 |
| Janssen Biotech, Inc. Nov 4, 2025 | Travel and Lodging TREMFYA · Immunology · travel to HAMPTON, VA | $29.40 |
| Janssen Biotech, Inc. Nov 3, 2025 | Travel and Lodging TREMFYA · Immunology · travel to VIRGINIA BEACH, VA | $21.00 |
| Regeneron Healthcare Solutions, Inc. Mar 27, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $6.77 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $15,024 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Completed · NCT06130566 - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.